# A Study Exploring the Use of Vaccine and Antigen Challenges for Immune Monitoring in Healthy Participants

> **NCT03953196** · EARLY_PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 48 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** Imvanex
- **BIOLOGICAL:** Shingrix
- **BIOLOGICAL:** LPS
- **BIOLOGICAL:** Candin
- **OTHER:** Skin Biopsy
- **OTHER:** Saline Control

## Key facts

- **NCT ID:** NCT03953196
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-08
- **Primary completion:** 2019-12-26
- **Final completion:** 2019-12-26
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03953196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03953196, "A Study Exploring the Use of Vaccine and Antigen Challenges for Immune Monitoring in Healthy Participants". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03953196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*